These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 12610189

  • 1. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG.
    J Clin Oncol; 2003 Mar 01; 21(5):884-90. PubMed ID: 12610189
    [Abstract] [Full Text] [Related]

  • 2. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S.
    J Clin Oncol; 1997 Feb 01; 15(2):796-807. PubMed ID: 9053507
    [Abstract] [Full Text] [Related]

  • 3. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S.
    Cancer Res; 1993 Mar 01; 53(5):1043-50. PubMed ID: 8439951
    [Abstract] [Full Text] [Related]

  • 4. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
    Meijer SL, Dols A, Urba WJ, Hu HM, Smith II JW, Vetto J, Wood W, Doran T, Chu Y, Sayaharuban P, Alvord WG, Fox BA.
    J Immunother; 2002 Mar 01; 25(4):359-72. PubMed ID: 12142559
    [Abstract] [Full Text] [Related]

  • 5. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer.
    Chang AE, Li Q, Jiang G, Teknos TN, Chepeha DB, Bradford CR.
    Head Neck; 2003 Mar 01; 25(3):198-209. PubMed ID: 12599287
    [Abstract] [Full Text] [Related]

  • 6. Immunological effects of BCG as an adjuvant in autologous tumor vaccines.
    Li Q, Normolle DP, Sayre DM, Zeng X, Sun R, Jiang G, Redman BD, Chang AE.
    Clin Immunol; 2000 Jan 01; 94(1):64-72. PubMed ID: 10607491
    [Abstract] [Full Text] [Related]

  • 7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ.
    J Clin Oncol; 1995 Aug 01; 13(8):1939-49. PubMed ID: 7636534
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A, Tso CL, Kaboo R, Pang S, Pierce W, deKernion JB, Figlin R.
    J Immunother Emphasis Tumor Immunol; 1996 Mar 01; 19(2):149-61. PubMed ID: 8732698
    [Abstract] [Full Text] [Related]

  • 15. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
    Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL.
    J Immunother Emphasis Tumor Immunol; 1996 Sep 01; 19(5):364-74. PubMed ID: 8941876
    [Abstract] [Full Text] [Related]

  • 16. Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.
    Steger GG, Pierce WC, Figlin R, Czernin J, Kaboo R, DeKernion JB, Okarma T, Belldegrun A.
    Clin Immunol Immunopathol; 1994 Aug 01; 72(2):237-47. PubMed ID: 8050198
    [Abstract] [Full Text] [Related]

  • 17. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
    Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL.
    Cancer Res; 1993 Oct 15; 53(20):4745-9. PubMed ID: 8402652
    [Abstract] [Full Text] [Related]

  • 18. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Bukowski RM, Sharfman W, Murthy S, Rayman P, Tubbs R, Alexander J, Budd GT, Sergi JS, Bauer L, Gibson V.
    Cancer Res; 1991 Aug 15; 51(16):4199-205. PubMed ID: 1868441
    [Abstract] [Full Text] [Related]

  • 19. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
    Belldegrun A, Pierce W, Kaboo R, Tso CL, Shau H, Turcillo P, Moldawer N, Golub S, deKernion J, Figlin R.
    J Urol; 1993 Nov 15; 150(5 Pt 1):1384-90. PubMed ID: 8411405
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard JJ, Lesimple T, Catros-Quemener V.
    Eur Cytokine Netw; 2000 Jun 15; 11(2):217-24. PubMed ID: 10903800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.